Modulation of Interleukin (IL)-13 Binding and Signaling by the gamma c Chain of the IL-2 Receptor*

(Received for publication, December 19, 1996, and in revised form, April 23, 1997)

Nicholas I. Obiri Dagger §, Takashi Murata Dagger , Waldemar Debinski and Raj K. Puri Dagger §

From the Dagger  Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892 and the  Division of Neurosurgery, Department of Surgery, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Interleukin (IL)-13 and IL-4 are cytokine products of TH2 cells which exert similar effects in a variety of cell types. We recently described IL-13R expression on human renal cell and colon carcinoma cells and demonstrated that gamma c is not a component of IL-13R or IL-4R systems in these cells. In lymphoid cells such as B cells and monocytes, which respond to IL-13, gamma c is a component of IL-4R but does not appear to be a component of IL-13R. Furthermore, while significant IL-13 binding is observed on carcinoma cells, IL-13 barely binds these lymphoid cells and the binding characteristics are different. To better understand the role of gamma c in IL-13 binding and signaling, we have transfected a renal cell carcinoma cell line with gamma c and examined IL-13 and IL-4 binding and signaling. IL-13 binding as well as IL-13 and IL-4 signaling through the JAK-STAT signaling pathway were severely inhibited. This inhibition was paralleled by a loss of expression of one of the IL-13R chains and intercellular cell adhesion molecule-1. Thus, although gamma c has been shown to enhance IL-4 binding and function in some cell types, its influence on IL-13R function in tumor cells appear to be largely negative.


INTRODUCTION

Interleukin-13 (IL-13)1 and IL-4 are pleiotropic immune regulatory cytokines, which are predominantly produced by activated lymphocytes. Both cytokines mediate similar effects on B cells and monocytes; however, IL-13 has not been shown to have direct effects on T cells (1-3). The effects of both cytokines are mediated by cell surface receptors (R) that are specific for each of these ligands (4, 5). The receptor for IL-4 has been extensively investigated and its structure appears to vary with cell types. We have proposed three models for the structure of the IL-4R complex (6). However, despite their structural differences, all of the identified forms of the IL-4R complex are quite effective in transducing signals in response to IL-4 binding.

Unlike the IL-4 receptor system, the receptor for IL-13 has not been well characterized. We have demonstrated that RCC cells express a large number of IL-13 binding sites and that these cells respond to IL-13 (4, 7). Cross-linking studies indicate that the IL-13R is predominantly composed of a ~65-70-kDa protein (4). RCC cells also express IL-4R, and 125I-IL-4 cross-links to IL-4Rbeta (the p140 chain of IL-4R) and a 65-70-kDa IL-4-binding protein. The inhibition of IL-4 binding to both proteins by IL-13 supports the notion that IL-4 and IL-13 receptors are structurally and functionally interrelated (4, 7-10). We recently proposed several models to account for the complex interactions among IL-13, IL-4, and the receptors for these ligands as they are expressed in different cell types. We proposed that IL-13R shares IL-4Rbeta (p140) and IL-4Ralpha (p70) with the IL-13R system in certain cell types (11). We had also predicted that IL-13 binds to a heterodimer consisting of two ~70-kDa proteins, one of which binds IL-13 alone (we termed this IL-13Ralpha ) while the other binds IL-13 as well as IL-4 (we termed this IL-13Ralpha ') (7, 11). The genes for a murine IL-13-binding protein, its human homologue, and a second human IL-13-binding protein were subsequently identified and characterized (12-14). The two human IL-13R genes encode 65-70-kDa proteins with different IL-13 binding characteristics. One of these (corresponding to our IL-13Ralpha ') requires IL-4Rbeta to bind and transduce IL-13 signal (14), while the other (corresponding to our IL-13Ralpha ) can bind IL-13 in the absence of IL-4Rbeta , but its role in IL-13 signaling remains unclear (13). Whether other as yet unidentified proteins are required to constitute a functional high affinity IL-13R remains to be resolved.

The IL-2Rgamma chain termed gamma c is shared by receptors for IL-4, IL-7, IL-9, and IL-15 on immune cells (15-18). It was hypothesized that IL-2Rgamma c is also a component of the IL-13R system (15). However, we have reported that an anti-gamma c antibody did not immunoprecipitate any 125I-IL-13-bound protein from RCC (4) or colon carcinoma (6) cell lysates, indicating that the gamma c protein may not be directly involved in IL-13 binding. The gamma c protein was not expressed in these cells. However, whether gamma c affects IL-13 binding in cells that normally express it is not known. It is also not known whether gamma c affects IL-13R structure and signal transduction.

In this study, we have examined the effect of the gamma c chain on IL-13 and IL-4 binding and signaling. We have transfected ML-RCC cells with the gamma c cDNA and examined its influence on certain biological responses of these cells to IL-13 and IL-4. We present evidence that gamma c severely decreased the IL-13 binding capacity of these cells and prevented the expression of the alpha  chain of the IL-13 receptor as well as ICAM-1. Furthermore, although gamma c had no significant effect on the binding of IL-4 to its receptors, its presence altered IL-13 and IL-4 signaling pathways in these cells in several ways, including the inhibition of IL-13- and IL-4-induced STAT-6 activation.


EXPERIMENTAL PROCEDURES

Cytokines and Reagents

Recombinant human IL-13 (rhIL-13) was expressed in Escherichia coli and purified as described previously (4). Recombinant human IL-4 was kindly provided by Dr. Michael Widmer of Immunex Corp., Seattle, WA. Antibodies to JAKs 1 and 2 and biotin-anti-phosphotyrosine (4G10) were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Antibodies to gamma c, JAK3, Tyk2, and STATs 3, 4, and 6 were purchased from Santa Cruz (Santa Cruz, CA). Antibodies to STAT1 and STAT5 were provided by Dr. David Finbloom (Center for Biologics Evaluation and Research, Food and Drug Administration (CBER, FDA), Bethesda, MD).

Cells

The ML-RCC (synonym: MA-RCC) renal cell carcinoma cell line was established in our laboratory as described previously (19) from primary surgical tissues and was maintained in HEPES-buffered Dulbecco's modified Eagle's medium with high glucose supplemented with glutamine plus 10% fetal calf serum and antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin).

Transfection of ML-RCC Cells

ML-RCC cells (3 × 105) were plated in 12-well tissue culture plates and cultured overnight. They were then transfected with a mixture of cDNAs encoding the genes for the gamma c subunit of the IL-2 receptor or neomycin transferase or both. Transfection was effected by the calcium phosphate method using the PROFECTANT kit (Promega) according to the manufacturer's instruction. Neomycin-resistant transfectants were selected by incubating the transfected cells in 0.8 mg/ml active G418 for 10 days. Selected cells were examined by Northern blot analysis to identify clones containing the gamma c gene in addition to the neomycin resistance gene. Two such clones isolated from the ML-RCC cell line were identified as MLgamma c. Clones transfected with the neomycin resistance but not the gamma c gene (MLneo) were used as negative controls for the double transfectants. Additional negative control transfectants (i.e. neomycin-resistant, gamma c (-)) were generated by using a recombination deficient retroviral vector to introduce the neomycin resistance gene into the target ML-RCC cells. This was achieved by infecting target cells with supernatant generated by the amphotropic retroviral vector-producing PA317 cell line (20), kindly provided by Dr. Carolyn Wilson (CBER, FDA). Identical results were observed when all negative control and parental cell lines were used in all tests. Similarly the two gamma c-positive clones (MLgamma c) were identical in their responses to all tests performed.

Northern Blot Analysis

Cells were harvested from culture with Versene (Bio-Whittaker, Walkersville, MD), washed, and total RNA isolated in a one-step procedure using Trizol (Life Technologies, Inc.) according to manufacturer's instructions. Aliquots of total RNA were electrophoresed through agarose (0.8%)/formaldehyde denaturing gel, transferred to a nylon membrane (S & S Nytran; Schleicher & Schuell) by capillary action and immobilized by ultraviolet cross-linking (Stratagene, Inc., La Jolla, CA). The membrane was then prehybridized overnight at 42 °C and hybridized with a 32P-labeled cDNA probe for gamma c at 42 °C for 18 h. The membrane was subsequently exposed to an X-AR film (Eastman Kodak Co.) to obtain an autoradiograph. To evaluate the amount of RNA loaded per lane, the blots were stripped and reprobed with 32P-labeled GAPDH cDNA.

Radioreceptor Binding Assay

rhIL-13 and rhIL-4 were labeled with 125I (Amersham Research Products) by using IODO-GEN reagent (Pierce) according to the manufacturer's instructions. The specific activity of the radiolabeled cytokines was estimated to range from 20 to 80 µCi/µg of protein for 125I-IL-4 and 40-120 µCi/µg for 125I-IL-13. Binding experiments were performed as described previously (4). Typically, 1 × 106 cells were incubated at 4 °C for 3-5 h with 125I-IL-13 (100-500 pM) or 125I-IL-4 (100-500 pM) in the presence or absence of increasing concentrations (up to 1000 nM) of unlabeled IL-13 or IL-4. The data were analyzed with the LIGAND (21) program to determine the number of binding sites/cell as well as binding affinity.

Flow Cytometry

MLgamma c RCC cells as well as MLneo control cells were cultured at 1 × 105 cells/ml in medium containing IL-4 or IL-13 (0-10 ng/ml) over a 48-h period. Cells were washed and incubated with a fluorescein isothiocyanate (FITC)-conjugated anti-human ICAM-1 antibody (Immunotech/Coulter) at a concentration of 40 µg/ml in FACS staining buffer (phosphate-buffered saline containing 0.1% fetal bovine serum, 2.5 mM EDTA, and 0.1% sodium azide) at 4 °C for 60 min. Control cells were incubated in FACS staining buffer alone or FITC-conjugated IgG1 (isotype control antibody). The cells were subsequently washed and fluorescence data collected on a FACScan/C32 equipment (Becton Dickinson, San Jose, CA). The data were analyzed with a LYSIS II software program, and fluorescence intensity was expressed as mean channel number on a 256-channel/104 log scale.

Affinity Cross-linking Studies

Cells (5-10 × 106) were incubated with 125I-IL-13 in the presence or absence of excess IL-13 or IL-4 for 2 h at 4 °C. The bound ligand was cross-linked to its receptor with disuccinimidyl suberate (Pierce) at a final concentration of 2 mM for 30 min. Cells were lysed in lysis buffer consisting of 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.02 mM leupeptin, 5.0 µM trypsin inhibitor, 10 mM benzamidine HCl, 1 mM phenanthroline, iodoacetamide, 50 mM aminocaproic acid, 10 µg/ml pepstatin, and 10 µg/ml aprotinin. The cell lysates were precleared and cleared by boiling in sample buffer containing 2-mercaptoethanol and analyzed by electrophoresis through an 8% SDS-polyacrylamide gel. The gel was subsequently dried and autoradiographed. In some instances, the receptor-ligand complex was captured from the precleared total cell lysate on protein A-Sepharose beads previously incubated with specific antibodies. The complex was washed in lysis buffer, boiled in sample buffer, and analyzed by SDS-PAGE.

Immunoprecipitation and Immunoblotting

ML-RCC cells (2 × 107) were incubated with 250 ng/ml IL-13 or 50 ng/ml IL-4 or left untreated as control for 10 min at 37 °C. The reactions were quenched by addition of 10 ml of PBS containing 1 mM sodium vanadate, 25 mM NaF, 10 mM sodium pyrophosphate, and 1 mM EDTA. The cells were lysed at 4 °C with 1% Nonidet P-40, 300 mM NaCl, 50 mM Tris (pH 7.4), leupeptin (10 mg/ml), aprotinin (10 mg/ml), phenylmethylsulfonyl fluoride (1 mM), 1 mM sodium vanadate, 25 mM NaF, 10 mM sodium pyrophosphate, and 1 mM EDTA. The cell lysates were precleared by incubation with protein A-Sepharose beads (Sigma). They were then incubated with protein A-Sepharose beads that had been preincubated with primary antibody for 2 h at 4 °C. The resulting complex was washed five times in lysis buffer, resuspended in loading buffer (NOVEX), and separated through 8% SDS-polyacrylamide gel. Separated proteins were transferred to PVDF membrane (NOVEX) for 1 h. The blots were washed three times in TBS-T buffer (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween 20), followed by 1 h of incubation in horseradish peroxidase-conjugated goat anti-rabbit or strepto-avidin (Amersham), depending on the nature of the primary antibody, followed by three washes. The blots were incubated with RENAISSANCETM chemiluminescence substrate mixture according to the manufacturer's instructions (NEN Life Science Products) for 1 min and exposed to x-ray film for 1-30 min.

Electrophoretic Mobility Shift Assay (EMSA)

After treatment with/without IL-13 (250 ng/ml) or IL-4 (50 ng/ml), cells were washed in cold PBS and solubilized with cold whole cell extraction buffer (1 mM MgCl2, 20 mM HEPES, pH 7.0, 10 mM KCl, 300 mM NaCl, 0.5 mM dithiothreitol, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 20% glycerol). DNA-binding proteins were identified by EMSA by using bandshift kit from Pharmacia Biotech Inc. Briefly, 30 µg of protein samples were incubated for 20 min at room temperature with 1 ng of 32P-labeled oligonucleotide probe consisting of double-stranded GRR (5'-AGCATGTTTCAAGGATTTGAGATGTATTTCCCAGAAAAG-3') of the promoter of the FcRgamma 1 gene in 20 µl of binding buffer (10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.5 mM dithiothreitol, 10% glycerol, 0.05% Nonidet P-40, 0.05 mg/ml poly(dI-dC)·(dI-dC)). A 200-fold excess of cold GRR probe was added as a competitor. Before loading, 10 × loading dye was added to each sample and separated in a 5% non-reducing polyacrylamide gel at 150 V for 2.5 h. Gels were dried for 2 h and autoradiographed overnight at room temperature. For the supershift assay, cell lysates were preincubated with preimmune rabbit serum as a control or STAT1, 3, 4, 5, and 6 antibodies on ice for 30 min, standard EMSA was then performed as described above.


RESULTS

Transfection of IL-2R gamma  Chain into RCC Cells

Two gamma c mRNA-positive (+) clones of ML-RCC (MLgamma c) were selected from five neomycin-resistant (MLneo) clones. As shown in Fig. 1A, alternatively spliced gamma c mRNA (16) was detected in MLgamma c but not in MLneo cells. Both of the MLgamma c clones were tested in all experiments shown, and both yielded identical results. Similarly, all the negative control clones (MLneo) yielded identical results in tests performed. To confirm that the gamma c mRNA being transcribed was also being properly translated into its protein in MLgamma c cell lines, we examined total cell lysates from these gamma c mRNA+ cell lines for the presence of gamma c protein by immunoprecipitation and Western blot analysis. The results indicate that MLgamma c cells expressed the gamma c protein as detected by anti-gamma c antibody, whereas the control and untransfected parental cell lines were negative (Fig. 1B). We have also demonstrated gamma c protein expression on the surface of these gamma c mRNA+ cells by flow cytometry (22). Following gamma c transfection, the MLgamma c clones took on a different morphology, appearing smaller and more elongated than the neomycin-resistant control cell lines (data not shown).


Fig. 1.

A and B, expression of gamma c mRNA and protein in MLgamma c cells. Ten micrograms of total RNA from ML-RCC cells transfected with gamma c and/or neomycin phosphotransferase cDNA as described under "Experimental Procedures" was fractionated over formaldehyde denaturing agarose gel, transferred to a nylon membrane support, and hybridized with a 32P-labeled gamma c cDNA probe as described previously (4). Blots were stripped and rehybridized with 32P-labeled cDNA probe for GAPDH (lower panel, A). MLgamma c and MLneo cells (10 × 106) were lysed at 4 °C with 1% Nonidet P-40 containing protease inhibitors as described under "Experimental Procedures." Proteins in the cell lysate were separated by SDS-PAGE and transferred to a PVDF membrane (NOVEX) for Western blotting using a gamma c specific antibody. Detection was achieved by chemiluminescence using RENAISSANCE reagents (NEN Life Science Products). Molecular size standards are shown on the left of the gel (B). C, affinity cross-linking and immunoprecipitation. MLgamma c and MLneo cells (7 × 107cells/ml) were incubated with 5 nM 125I-IL-13 for 2 h at 4 °C. 125I-IL-13 was cross-linked to its receptor with disuccinimidyl suberate (2 mM), and total cell lysate was prepared from the cells, precleared in protein A-Sepharose beads. Some lysates were incubated with protein A-Sepharose beads previously incubated with gamma c-specific antibody. The immunoprecipitated complex (IP) as well as the 125I-IL-13·IL-13R complex were analyzed by SDS-PAGE as described (4).


[View Larger Version of this Image (17K GIF file)]

Association of Transfected gamma c Chain with IL-13R in ML-RCC Cells

Since gamma c modulated the binding of IL-13 to its plasma membrane receptors, it was important to determine whether the gamma c protein expressed in ML-RCC cells transfected with the gamma c cDNA is associated with IL-13 receptor proteins. We cross-linked 125I-IL-13 to its receptors on gamma c-transfected and control cells. The cell lysate from each group was subsequently incubated with anti-gamma c antibody, and the resulting antigen-antibody complex was analyzed by SDS-PAGE. The gel was overexposed (5 days) to ensure visualization of the IL-13/gamma c band. The results (Fig. 1C) indicate the formation of an 125I-IL-13·IL-13R complex of 58-65 kDa in MLgamma c cells. Furthermore, the gamma c protein could be immunoprecipitated from this band in MLgamma c as a faint ~60-kDa band (Fig. 1C) but not from the control MLneo cell line (data not shown).

Effect of gamma c on IL-13 and IL-4 Binding to Their Receptors

Since gamma c has previously been shown to increase the binding affinity of certain cytokine ligands to their receptor (15-18), we examined its effect on IL-13 binding to MLgamma c and MLneo cells by performing 125I-IL-13 equilibrium binding assays. The results (Table I, Fig. 2, A and B) show that the neoR+ control RCC cells (MLneo) significantly bound 125I-IL-13, and this binding was specific as it was displaced by increasing concentrations of the unlabeled ligand (Fig. 2). However, introduction of the gamma c chain into these cells resulted in a drastic reduction of 125I-IL-13 binding. For example, assuming a 1:1 ratio of radiolabeled ligand to cell surface receptor, an analysis of the 125I-IL-13 binding data with the LIGAND program (21) indicates that neoR+ control MLneo cell lines express 480 ± 86 × 103 (mean ± S.D.) IL-13 binding sites/cell, and the number of binding sites/cell on the parental cell line, ML-RCC was determined to be 351 ± 90 × 103. However, in the gamma c-transfected MLgamma c, 125I-IL-13 binding was dramatically reduced (by up to 2 log orders) to 4080 ± 1890 binding sites/cell. It is interesting that, in addition to reducing the level of ligand binding, gamma c induced high affinity 125I-IL-13 binding to RCC cells (Fig. 2B). For example, ML and MLneo cells bound 125I-IL-13 with a dissociation constant (Kd) ranging from 7.5 to 20.5 nM (mean ± S.D. = 13.4 ± 4.6 nM), but in MLgamma c, the Kd value (mean ± S.D.) was 0.23 nM ± 0.14 (n = 4) (Table I). In some experiments, analysis of the binding data with the LIGAND program (21) indicated a concurrent expression of a lower affinity IL-13R (Kd = 7.5 nM) (Fig. 2B).

Table I. Effect of gamma c on IL-13 receptor expression in ML-RCC cells


Cell line Treatment Binding sites/cella Kd

nM
ML-RCC None (parental cell line) 248  × 103 7.50
415  × 103 8.95
391  × 103 16.70
MLneob Retrovirally transfected 369  × 103 11.10
613  × 103 12.90
480  × 103 20.50
MLneo Transfected by CaPO4 472  × 103 16.00
467  × 103 19.60
MLgamma cc Transfected by CaPO4 1.5  × 103 0.11
4.06  × 103 0.19
5.98  × 103 0.39
2.2  × 103 0.11

a Determined from 125I-IL-13 displacement studies in which 100 pM 125I-IL-13 was incubated with cells at 4 °C for 4-5 h in the presence of 0-500 nM IL-13. The binding data were analyzed with the LIGAND program.
b ML-RCC cells transfected with neomycin transferase II cDNA as described under "Experimental Procedures."
c ML-RCC cells transfected with gamma c cDNA as described under "Experimental Procedures."


Fig. 2.

125I-IL-13 binding in MLgamma c and MLneo cells. Equilibrium binding studies were performed on gamma c-transfected (MLgamma c) and control (MLneo) ML-RCC cells by incubating 1 × 106 cells with 100-500 pM 125I-IL-13 for 2-5 h. Increasing concentrations (0-1000 nM) of unlabeled IL-13 were added to compete the binding of the radiolabeled ligand. Cell-bound radioactivity was determined with a gamma  counter and the data analyzed with the LIGAND program (21). Binding data are shown in A, while a Scatchard plot of the data is shown in B. IL-4R and IL-13R expression in control (MLneo) and gamma c-transfected (MLgamma c) cells was also analyzed by direct binding to 2 nM 125I-IL-4 or 125I-IL-13. Nonspecific binding was determined by including excess unlabeled IL-4 or IL-13 in the binding tube and was subtracted from total binding values to obtain specific binding data (C).


[View Larger Version of this Image (14K GIF file)]

Since IL-4R expression is much more limited in ML-RCC cells, we compared the effect of gamma c on IL-4 binding in MLneo and MLgamma c cells by a direct binding assay using a saturating concentration of 125I-IL-4 and 125I-IL-13. Our results (Fig. 2C) show that in comparison to the profound decrease in IL-13R expression induced by gamma c, IL-4R expression is not significantly affected.

Modulation of IL-13Ralpha and IL-13Ralpha ' mRNA Expression by gamma c

Since gamma c inhibited IL-13 binding and IL-13Ralpha and IL-13Ralpha ' chains were recently cloned, we were interested to examine whether one or both chains were modulated by the presence of gamma c in ML-RCC. By Northern analysis, we found that IL-13Ralpha mRNA is expressed in MLneo but not in MLgamma c cells (Fig. 3, upper panel). The expression of IL-13Ralpha ' mRNA was reduced in MLgamma c in comparison to MLneo (Fig. 3, middle panel). When we normalized IL-13Ralpha ' mRNA band to the GAPDH mRNA band in each cell type for comparison, we observed that IL-13Ralpha ' expression is about 3 times higher in MLneo than in MLgamma c.


Fig. 3. Effect of gamma c on IL-13Ralpha and IL-13Ralpha ' expression. Total RNA was isolated from MLgamma c and MLneo cells, and 10 µg from each preparation was examined for the presence of mRNA for the two known chains of IL13R (13, 14) by Northern blot analysis. The cDNA for these genes, provided by Dr. Warren Leonard (NHLBI, NIH, Bethesda, MD) and Dr. P. Ferrara (Sanofi, Labege Cedex, France) were labeled with 32P and used as probes. The filter was subsequently stripped and reprobed for GAPDH (bottom panel).
[View Larger Version of this Image (30K GIF file)]

Modulation of ICAM-1 Expression by gamma c

Since gamma c modulated IL-13 binding and appeared to alter the morphology of gamma c-transfected cells, we further investigated its role in ML-RCC cells by examining the effect of IL-13 and IL-4 on the surface expression of ICAM-1 molecules. Consistent with our previous findings (4, 23), the control MLneo cell line had considerable baseline expression of ICAM-1 (Fig. 4A, left panel), which was significantly enhanced by IL-13 or IL-4 treatment. However, transfection of gamma c inhibited the basal level of ICAM-1 expression in MLgamma c and neither IL-13 nor IL-4 could reverse this inhibition (Fig. 4A, right panel). Additionally, we examined the effect of gamma c on ICAM-1 mRNA expression by Northern analysis. Our results show that in the gamma c-positive MLgamma c cells (Fig. 4B, right lane) ICAM-1 mRNA is not expressed, but it is expressed in the gamma c-negative MLneo and the parental ML-RCC cells (two left lanes).


Fig. 4. Effect of gamma c on ICAM-1 expression. MLgamma c RCC cells containing gamma c cDNA as well as gamma c-control MLneo cells were cultured at 1 × 105 cells/ml in medium containing IL-4 or IL-13 (10 ng/ml) over a 48-h period. Cells (4-6 × 105/sample) were washed and examined for surface ICAM-1 expression by flow cytometry as described under "Experimental Procedures." Fluorescence intensity (log10) expressed as mean channel number (MCN) is shown on the x axis. Cells cultured in medium only and stained with FITC-conjugated IgG1 (isotype control) were used as controls (A). ICAM-1 mRNA expression was examined in gamma c-positive MLgamma c and in gamma c-negative MLneo control cells by Northern analysis (B). Ten micrograms total mRNA was electrophoresed through formaldehyde/agarose denaturing gel and analyzed for ICAM-1 mRNA expression as described previously (23).
[View Larger Version of this Image (28K GIF file)]

Effect of gamma c on the Phosphorylation of JAK Kinase by IL-13 and IL-4

It has been shown that a number of cytokines including IL-13 and IL-4 can induce phosphorylation and activation of the Janus family of kinase (24-27). We recently demonstrated that colon carcinoma cells express JAK1, JAK2, and Tyk2 (6, 24) and that these kinases are phosphorylated by IL-4 and IL-13. JAK3 was not expressed and was not phosphorylated in these cells (24). In the present study, we examined the impact of the presence of gamma c chain on the IL-13- and IL-4-induced phosphorylation of JAK tyrosine kinase in ML-RCC cell lines. As shown in Fig. 5A, IL-4 induced the phosphorylation of JAK1 and JAK2 tyrosine kinase in ML cells. JAK1 kinase was weakly phosphorylated in response to IL-13, but in contrast to our previous observation in colon carcinoma cells (24), IL-13 did not induce phosphorylation of JAK2 in ML-RCC cells. Tyk2 kinase was constitutively phosphorylated, and this level of phosphorylation was not enhanced by either interleukin. In the gamma c(+) MLgamma c cells, JAK1 was constitutively phosphorylated and the level of phosphorylation was not affected by IL-4 or IL-13 treatment. JAK2 was weakly phosphorylated in unstimulated as well as in IL-13- or IL-4-treated groups and Tyk2 kinase was not detected. As previously observed in colon carcinoma cells (24), JAK3 kinase was neither expressed nor phosphorylated in MLneo and MLgamma c cells, although it was expressed and phosphorylated in the EBV-B cell line used as a positive control (Fig. 5B and Ref. 24). Thus, in gamma c-transfected MLgamma c cells, Tyk2 kinase was not expressed and IL-4 and IL-13 could not enhance or induce the phosphorylation of JAK1 and JAK2 otherwise seen in control ML cells.


Fig. 5. Effect of IL-13 and IL-4 on JAK kinase expression and phosphorylation in ML-RCC cells. Following IL-13 and IL-4 treatment of control and gamma c-transfected ML-RCC cells, cell lysate was prepared from each treatment group and immunoprecipitated (IP) with antibody against JAK1, JAK2, Tyk2, or JAK3. The resulting complex was washed three times in lysis buffer electrophoresed and transferred to PVDF membrane. The membrane was subsequently hybridized with anti-phosphotyrosine antibody (4G10) (A). To evaluate the quantity of JAK1, JAK2, and Tyk2 proteins available on the blot for phosphorylation, each blot was stripped and reprobed with specific antibody to the target proteins (bottom panel). ML-RCC and other renal cell carcinoma cell lines were examined for the expression of JAK3 with anti-JAK3 antibody as discussed under "Experimental Procedures." An Epstein-Barr virus-transformed B cell line (EBV-V cell) was included as a positive control (B).
[View Larger Version of this Image (26K GIF file)]

Effect of gamma c on the IL-13- and IL-4-mediated Activation of STAT Protein

We next investigated the effect of gamma c expression on STAT activation by performing EMSA on lysates from these cells. As shown in Fig. 6A, in gamma c-negative cells (ML and MLneo), NF (nuclear factor)-IL-4 was activated and bound to the labeled GRR probe in response to IL-13 or IL-4. However, in the gamma c-positive MLgamma c cells, NF-IL-4 was not activated in response to IL-13 or IL-4. We ascertained the specificity of the assay by incubating the labeled probe with a 200-fold excess unlabeled probe before running it on the gel. No NF-IL-4/GRR bands were observed in lanes containing these samples.


Fig. 6.

Effect of gamma c on IL-13- and IL-4-induced STAT phosphorylation and activation in ML-RCC cells. A, after treatment with medium, IL-13 (250 ng/ml), or IL-4 (50 ng/ml), cells (ML, MLgamma c, MLneo) were washed in cold PBS and solubilized with cold whole cell extraction buffer. DNA binding activity was determined by EMSA. Briefly, 30 µg of protein samples were incubated for 20 min at room temperature with 1 ng of 32P-labeled GRR probe in 20 µl of binding buffer. A 200-fold excess of cold GRR probe was added as a competitor. For the supershift assay (B), cell lysates were preincubated with preimmune rabbit serum as a control or STAT1, 3, 4, 5, and 6 antibodies on ice for 30 min; standard EMSA was then performed as described above. C, following IL-13 and IL-4 treatment, cells were lysed in lysing buffer and STAT6 protein was immunoprecipitated (IP) with specific antibody. The complex was separated by SDS-PAGE and transferred onto PVDF membrane. STAT6 phosphorylation was detected by anti-phosphotyrosine antibody (4G10) (upper panel). STAT6 protein expression was confirmed by reprobing the stripped blot with STAT6 antibody (lower panel).


[View Larger Version of this Image (38K GIF file)]

To confirm the identity of the STAT protein which was activated in response to IL-4 and IL-13 in ML and MLneo RCC cells, we next performed the supershift assay. The results (Fig. 6B) show that the binding of NF-IL-4 in the IL-4-treated ML group is not affected by preincubation in normal serum or in antibodies specific for STATs 1, 3, 4, or 5, whereas the band representing the bound NF-IL-4 was not visible when the lysate was preincubated in anti-STAT6 antibody. These results indicate that NF-IL-4 corresponds to STAT6 and the other STATs were not activated in response to IL-4 in ML cells. In the gamma c-positive cells (MLgamma c), no STAT protein was activated in response to IL-4.

To further investigate the mechanism underlying the gamma c inhibition of STAT6 activation, we examined the phosphorylation of STAT6 protein from gamma c(+) and gamma c(-) ML-RCC cells in response to IL-13 and IL-4 by immunoprecipitation and immunoblotting. As shown in Fig. 6C, while IL-13 and IL-4 treatment induced STAT6 phosphorylation in the parental ML and the control neoR+ transfectant (MLneo) cell lines, STAT6 phosphorylation was not induced in the gamma c(+) MLgamma c cell line (left panel). These results indicate that gamma c inhibited the IL-4- and IL-13-mediated activation of STAT6 by inhibiting its phosphorylation.


DISCUSSION

In our initial characterization of IL-13 binding, we noted that while IL-13 was able to displace or inhibit IL-4 binding to RCC cells, which lack gamma c expression, it did not inhibit IL-4 binding in Raji B and MLA144 T lymphoid cells in which gamma c is highly expressed. Furthermore, we noted that B cells and monocytes which are highly responsive to IL-13 express very few IL-13R (4). This led us to further explore the role of gamma c in IL-13 binding. In this report, we have demonstrated that the gamma c protein can exert a profound influence on the binding of IL-13 to its receptors and on the signal transduction pathways of IL-13 and IL-4 following ligand binding. Expression of gamma c in ML-RCC profoundly inhibited IL-13 binding, IL-13-induced signaling, and ICAM-1 expression. Although IL-4 binding was not affected by gamma c expression, IL-4-induced signaling was also impaired in the gamma c-transfected cell line and IL-4 failed to induce ICAM-1 expression in these cells.

Our results regarding the expression of gamma c in cells that co-express IL-4R and IL-13R demonstrate that gamma c expression is disruptive to the expression of the alpha  chain of the IL-13R while diminishing IL-13Ralpha ' expression, and may be responsible for the reduction in IL-13 binding. On a broader scale, this may explain why gamma c-positive cells such as B cells, monocytes, and TF-1 cell lines, which are very responsive to IL-13, have been shown to express low levels of IL-13R. Similarly, the failure of IL-13 to compete for the binding of IL-4 on MLA 144 and Raji B lymphoblastoid cell line (4) otherwise seen in other cell types (4, 8, 10, 25) may be due to the high gamma c content of these cells and the consequent deficiency in IL-13Ralpha expression.

It is of interest that the gamma c protein affected IL-13R rather than IL-4R in this manner because, although previous studies have shown that gamma c is a natural component of IL-4R in a number of cell types, it has not been identified as a natural component of IL-13R in any cell type examined thus far (11). In a study carried out with COS-7 cells, the inhibition of IL-13 but not IL-4 binding by gamma c was demonstrated (13). However, the biologic consequences of the observation were not addressed. Our results demonstrate that gamma c has the potential to physically interact with components of native IL-13 signaling pathway and exert a downstream effect. Consistent with this concept, gamma c expression altered the pattern of intracellular signaling in response to IL-13. For example, IL-13 has been shown to cause the phosphorylation and activation of JAK1 and Tyk2 tyrosine kinase in hematopoietic cells and JAK1, JAK2, and Tyk2 in non-hematopoietic cells (6, 24-31). However, in the current study, phosphorylation of JAK2 and Tyk2 was not seen in gamma c-transfected MLgamma c cells. Similarly, IL-13 failed to induce the phosphorylation of JAK-1 kinase in gamma c-transfected cells, although IL-13 induced the phosphorylation of JAK1 in control cells. Tyk2 was constitutively phosphorylated in control cells, and IL-13 did not modulate its phosphorylation. In gamma c-transfected cells, neither constitutive nor IL-13-induced phosphorylation of Tyk2 was observed. These results suggest that the expression of gamma c leads to an inhibition of IL-13-mediated activation of JAK kinase in ML-RCC cell line and that IL-13Ralpha may play a pivotal role in these signaling events.

The activation of JAK kinase has been shown to cause the phosphorylation and activation of STAT proteins. We therefore evaluated phosphorylation and activation of STAT proteins in control and gamma c-transfected MLgamma c cells as well as the effects of IL-13 on these events. It is of interest to note that IL-13 phosphorylated and activated STAT6 protein in control cells but not in gamma c-transfected MLgamma c cells. These data suggest that gamma c expression and the accompanying disruption of IL-13Ralpha and/or diminution of IL-13Ralpha ' expression inhibited not only the proximal events that result from IL-13 activation but the distal/terminal IL-13 and IL-4 signaling events as well. The results also suggest that IL-13Ralpha and IL-13Ralpha ' may be essential for the transduction of certain IL-4 and IL-13 signals supporting previous suggestions that the signal pathways for both cytokines converge at one or more points.

The reason for the profound decrease in IL-13 binding to gamma c-transfected ML cells is not completely known. However, our results suggest that IL13Ralpha is predominantly essential for IL-13 binding and its apparent displacement by gamma c in the IL-13R complex may be related to the drastic reduction in IL-13 binding. This structural modification of the IL-13R complex by gamma c may also have affected the affinity of its binding to IL-13. In this study, we evaluated IL-13 binding by 125I-IL-13 displacement assays and our results suggest that the affinity of IL-13 binding is lower in MLneo than in MLgamma c. However, in other studies,2 we have proposed a different model for the analysis of IL-13 binding to these cells, which may be more appropriate for addressing the apparent cluster distribution of IL-13R on these cells. While gamma c may have favored high affinity IL-13 binding, it may also have disrupted necessary interactions between the different chains of IL-4R and IL-13R through the sequestration of IL-4Rbeta by gamma c.

The loss of IL-4 and IL-13 signaling in MLgamma c may also have resulted from a disruption of necessary interactions between the intracellular domains of the receptor for IL-4 and IL-13. It was recently shown that the IL-4Rbeta protein undergoes homodimerization for IL-4 signaling and that gamma c is not required for the phosphorylation and activation of STAT6 protein (32, 33). Although there is no direct evidence that the different intracellular domains of IL-4R and IL-13R interact, IL-13 has been shown to phosphorylate IL-4Rbeta (24). Thus it is quite likely that the introduction of gamma c interferes with the assembly of a functional IL-4R complex, resulting in an impaired intracellular signaling by IL-4 and IL-13. It is also possible that the introduction of gamma c may have activated phosphatases whose activities could have resulted in the disruption of IL-13 and IL-4 signaling. Additional studies are necessary to address these possibilities.

We next examined the effect of gamma c on the functional response of ML-RCC cells to IL-4 and IL-13 stimulation. Surprisingly, in gamma c-transfected MLgamma c cells, there was a distinct change in morphology accompanied by a drastic diminution of ICAM-1 expression, and neither interleukin reversed these changes. The mechanism(s) underlying these changes is not clear but our results suggest that the disruption of IL-13Ralpha is directly or indirectly involved in a structural modification of the cytoskeletal framework of the cell to alter its shape and size. Whether this morphological effect is related to the loss of ICAM-1 expression is not clear. Alternatively, the introduction of gamma c into the cells may have turned off ICAM-1 gene expression and cellular responsiveness to IL-13 and IL-4. Additional studies are needed to improve our understanding of these events.

In summary, we have provided evidence for a novel role for gamma c protein in ML-RCC cells. Not only did this protein inhibit the binding of IL-13 to its receptor but, more importantly, it also inhibited intracellular signaling induced by IL-13 and IL-4. In addition, gamma c modified cellular function in these cells by inhibiting constitutive IL-13Ralpha and ICAM-1 expression, and this inhibition was not restored by IL-4 or IL-13. Our results suggest that an abnormal expression of gamma c may have significant disease implications with or without IL-13 and IL-4 involvement and that additional studies are needed to better understand the role of gamma c in tumor cell function.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Laboratory of Molecular Tumor Biology, Div. of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, HFM-530, Food and Drug Administration, National Institutes of Health-Bldg. 29B, Rm. 1E09B, 29 Lincoln Dr., MSC4555, Bethesda, MD 20892. Tel.: 301-827-0676; Fax: 301-827-0449; E-mail: obiri{at}a1.cber.fda.gov.
1   The abbreviations used are: IL, interleukin; R, receptor; rhIL, recombinant human IL; PVDF, polyvinylidene difluoride; PAGE, polyacrylamide gel electrophoresis; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; EMSA, electrophoretic mobility shift assay; NF, nuclear factor; ICAM, intercellular cell adhesion molecule; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
2   V. A. Kuznetsov, N. I. Obiri, and R. K. Puri, submitted for publication.

ACKNOWLEDGEMENTS

We acknowledge the expert assistance provided by Howard Mostowski (flow cytometry) and invaluable technical support provided by Pam Leland, both of CBER, FDA. We are grateful for useful discussions of the manuscript with Drs. Priti Mehrotra and Angus Grant (CBER, FDA). We also thank Dr. Warren Leonard (NHLBI, NIH) for kindly providing cDNAs for gamma c and IL-13Ralpha ' chain.


REFERENCES

  1. Minty, A., Chalon, P., Derocq, J.-M., Dumont, X., Guillemot, J.-C., Kaghad, M., Labit, C., Leplatois, P., Liauzum, P., Miloux, B., Minty, C., Casekkas, P., Loison, G., Lupker, J., Shire, D., Ferrara, P., and Caput, D. (1993) Nature 362, 248-250 [CrossRef][Medline] [Order article via Infotrieve]
  2. Puri, R. K., and Siegel, J. (1993) Cancer Invest. 11, 473-486 [Medline] [Order article via Infotrieve]
  3. Zurawski, G., and de Vries, J. E. (1994) Immunol. Today 15, 19-26 [CrossRef][Medline] [Order article via Infotrieve]
  4. Obiri, N. I., Debinski, W., Leonard, W. J., and Puri, R. K. (1995) J. Biol. Chem. 270, 8797-8804 [Abstract/Free Full Text]
  5. Idzerda, R. L., March, C. J., Mosley, B., Lyman, S. D., Bos, T. V., Gimpel, S. D., Din, W. S., Grabstein, K. H., Widmer, M. B., Park, L. S., Cosman, D., and Beckmann, M. P. (1990) J. Exp. Med. 171, 861-873 [Abstract]
  6. Murata, T., Noguchi, P. D., and Puri, R. K. (1995) J. Biol. Chem. 270, 30829-30836 [Abstract/Free Full Text]
  7. Obiri, N., Husain, S. R., Debinski, W., and Puri, R. K. (1996) Clin. Cancer Res. 2, 1743-49 [Abstract]
  8. Debinski, W., Obiri, N. I., Pastan, I., and Puri, R. K. (1995) J. Biol. Chem. 270, 16775-16780 [Abstract/Free Full Text]
  9. Zurawski, S. M., Vega, F. J., Huyghe, B., and Zurawski, G. (1993) EMBO J. 12, 2663-2670 [Abstract]
  10. Zurawski, S. M., Chomarat, P., Djossou, O., Bidaud, C., McKenzie, A. N. J., Miossec, P., Banchereau, J., and Zurawski, G. (1995) J. Biol. Chem. 270, 13869-13878 [Abstract/Free Full Text]
  11. Obiri, N. I., Dover, P., Murata, T., Debinski, W., and Puri, R. K. (1997) J. Immunol. 158, 756-764 [Abstract]
  12. Hilton, D. J., Zhang, J., Metcalf, D., Alexander, W. S., Nicola, N., A., and Wilson, T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 497-501 [Abstract/Free Full Text]
  13. Caput, D., Laurent, P., Kaghad, M., Lelias, J.-M., Lefort, S., Vita, N., and Ferrara, P. (1996) J. Biol. Chem. 271, 16921-16926 [Abstract/Free Full Text]
  14. Aman, M. J., Tayebi, N., Obiri, N. I., Puri, R. K., Modi, W. S., and Leonard, W. (1996) J. Biol. Chem. 271, 29265-270 [Abstract/Free Full Text]
  15. Russell, S. M., Keegan, A. D., Harada, N., Nakamura, Y., Noguchi, M., Leland, P., Freedman, M. C., Miyajima, A., Puri, R. K., Paul, W. E., and Leonard, W. J. (1993) Science 262, 1880-1883 [Medline] [Order article via Infotrieve]
  16. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., and Sugamura, K. (1992) Science 257, 379-382 [Medline] [Order article via Infotrieve]
  17. Noguchi, M., Nakamura, Y., Russell, S., Ziegler, S. F., Tsang, M., Cao, X., and Leonard, W. J. (1993) Science 262, 1877-1880 [Medline] [Order article via Infotrieve]
  18. Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. (1994) EMBO J. 13, 2822-2830 [Abstract]
  19. Obiri, N. I., Hillman, G., Haas, G. P., Sudha, S., and Puri, R. K. (1993) J. Clin. Invest. 91, 88-93 [Medline] [Order article via Infotrieve]
  20. Miller, D., and Buttimore, C. (1986) Mol. Cell. Biol. 6, 2895-2902 [Medline] [Order article via Infotrieve]
  21. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220-239 [Medline] [Order article via Infotrieve]
  22. Puri, R. K., Leland, P., Obiri, N. I., Husain, S. R., Mulé, J., Pastan, I., and Kreitman, R. J. (1996) Cell. Immunol. 171, 80-86 [CrossRef][Medline] [Order article via Infotrieve]
  23. Obiri, N. I., Tandon, N., and Puri, R. K. (1995) Int. J. Cancer 61, 635-42 [Medline] [Order article via Infotrieve]
  24. Murata, T., Noguchi, P., and Puri, R. K. (1996) J. Immunol. 156, 2972-78 [Abstract]
  25. Murata, T., and Puri, R. K. (1997) Cell. Immunol. 175, 33-40 [CrossRef][Medline] [Order article via Infotrieve]
  26. Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O., Goldman, A. S., Schmalstieg, F. C., Ihle, J. N., O'Shea, J. J., and Leonard, W. J. (1994) Science 266, 1042-1045 [Medline] [Order article via Infotrieve]
  27. Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z.-J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., and Yaniguchi, T. (1994) Science 266, 1045-1047 [Medline] [Order article via Infotrieve]
  28. Welham, M. J., Learmonth, L., Bone, H., and Schrader, J. W. (1995) J. Biol. Chem. 270, 12286-12296 [Abstract/Free Full Text]
  29. Malabarba, M. G., Kirken, R. A., Rui, H., Koettnitz, K., Kawamura, M., O'Shea, J. J., Kalthoff, F. S., and Farrar, W. L. (1995) J. Biol. Chem. 270, 9630-9637 [Abstract/Free Full Text]
  30. Keegan, A. D., Johnston, J. A., Tortolani, P. J., McReynolds, L. J., Kinzer, C., O'Shea, J. J., and Paul, W. E. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7681-7685 [Abstract]
  31. Izuhara, K., Heike, T., Otsuka, T., Yamaoka, K., Mayumi, M., Imamura, T., Niho, Y., and Harada, N. (1996) J. Biol. Chem. 271, 619-622 [Abstract/Free Full Text]
  32. Kammer, W., Lischke, A., Moriggl, R., Groner, B., Ziemiecki, A., Gurniak, B., Berg, L. J., and Friedrich, K. (1996) J. Biol. Chem. 271, 23634-23637 [Abstract/Free Full Text]
  33. Lai, S. Y., Molden, J., Liu, K. D., Puck, J. M., White, M. D., and Goldsmith, M. A. (1996) EMBO J. 15, 4506-4514 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.